KRAS and adenocarcinoma: Genetically modified mouse model demonstrated that not all KRAS-mutant lung cells equally developed to adenomas and malignant adenocarcinomas and only those derived from surfactant protein C + alveolar type II cells may progress to IVA (67, 68).